Previous Article | Next Article ![]()
Journal of Virology, December 2008, p. 12487-12497, Vol. 82, No. 24
0022-538X/08/$08.00+0 doi:10.1128/JVI.00877-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, People's Republic of China,1 College of Basic Medical Science, Harbin Medical University, Harbin 150081, People's Republic of China2
Received 24 April 2008/ Accepted 18 September 2008
|
|
|---|
|
|
|---|
One of the most prominent features of BDV infection is the heavy inflammatory reaction in the CNS and the rare degeneration of neurons in naturally infected hosts (25). In experimentally infected rats, the histopathology of the CNS is dependent on the immune status of the host at the time of inoculation, the genetic background, and the route of infection (33). The inoculation of immunocompetent adult rats with BDV results in marked immune-mediated meningoencephalitis consistent with the classical Borna disease. In the process of the persistent infection of BDV in adult rats, the degeneration of the neurons is observed. In contrast, immunoincompetent rats such as neonates show a tolerance to the infection of BDV without signs of Borna disease or encephalitis. Neonatal infection with the virus causes significant alterations in the development of the CNS (23). These studies provided evidence for direct effects of BDV infection on cellular functions in the absence of immunopathological degeneration.
The phosphoprotein (P) of BDV, an essential cofactor of virus RNA-dependent RNA polymerase, is regulated by protein kinase C
and casein kinase II (26) and binds to the N, X, and L proteins of BDV to modulate the active viral polymerase complex (24, 27, 28). Our recent study showed that BDV and its P protein could inhibit the expression of inducible nitric oxide synthase (iNOS) in astrocytes, suggesting that BDV establishes a persistent infection at least in part due to its inhibition of iNOS to impair immune responses (22). This viral protein also can counteract the expression of TBK-1-dependent beta interferon, and thus it can establish an antiviral state (34). Moreover, P protein binds directly to a multifunctional protein (HMGB-1) and represses p53-mediated transcriptional activity (14, 38). Finally, the expression of BDV P protein was demonstrated to induce behavioral and neurological abnormalities in transgenic mice (13).
Gamma-aminobutyric acid (GABA) exists predominantly in the brain, with glycine as one of the two inhibitory amino acid neural transmitters (20). Its receptor, GABA type A receptor (GABAA-R), is the principal GABA-gated ion channel (17) and plays important roles in pharmacology. GABAA-R acts as the target of benzodiazepine-related drugs, such as diazepam, triazolam, and alprazolam, which are widely used for the treatment of anxiety and insomnia. GABAA-R-associated protein (GABARAP) originally was identified as a linker between GABAA-Rs and microtubules. Recent study has demonstrated that GABARAP can interact with the
2 subunit of GABAA-R and has a functional effect on the regulation of GABA activities by disrupting the trafficking of GABAA-Rs to the cell membranes (4, 5).
In this study, we demonstrated that BDV P protein can bind directly to GABARAP both in vitro and in vivo by using different approaches. Biological effects of the interaction of P protein with GABARAP and the molecular mechanisms underlying the effects of P protein on the regulation of GABARAP and GABAA-Rs also were investigated and discussed.
|
|
|---|
Plasmid construction.
The plasmid pcDNA-P was kindly provided by Thorsten Wolff and Peter Staeheli. Plasmids pCMV-
1, pCMV-β2, and pRK5-
2L-GFPN (15), expressing the
1, β2, and
2 subunits of the GABAA-R, respectively, were kindly provided by Bill Wisden and Erwin Sigel. The P gene of BDV was amplified from pcDNA-P by PCR using primers 5'-TTTGGATCCATGGCAACGCGACCATCGAG-3' and 5'-TTTCTCGAGTGGTATGATGTCCCACTCATC-3'. The resulting PCR product then was subcloned into pET-28a to yield plasmid pET-28a-P. To generate pVP16-P, the P gene was amplified from pcDNA-P by PCR using primers 5'-CGCGGATCCCCATGGCAACGCGACCATC-3' and 5'-CCCAAGCTTTTATGGTATGATGTCCCAC-3', and the PCR product was subcloned into pVP16. To generate pEGFP-P, the P gene was amplified from pcDNA-P using primers 5'-CCCAAGCTTATGGCAACGCGACCATCG-3' and 5'-CGCGGATCCTTATGGTATGATGTCCCAC-3', and the PCR product then was subcloned into pEGFP-C3.
The GABARAP cDNA was amplified by PCR using primers 5'-CGCGGATCCGGATGAAGTTCGTGTACA-3' and 5'-CCCAAGCTTTCACAGACCGTAGACACT-3' to introduce BamHI and HindIII cloning sites and then was subcloned into appropriate restriction sites of plasmids pM, pET-28a, and pCMV-Tag2C to generate the plasmids pM-GABARAP, pET-28a-GABARAP, and pCMV-Tag2C-GABARAP, respectively. The GABARAP cDNA was amplified by PCR using primers 5'-CCCAAGCTTGGATGAAGTTCGTGTACA-3' and 5'-CGCGGATCCTCACAGACCGTAGACACT-3' and then subcloned into pAsRed2C1 to yield plasmid pAsRed2C1-GABARAP.
The mutant forms of the GABARAP and P genes in the expression plasmids were generated from the wild-type plasmid by using PCR and recloning techniques. The primers used in PCR to create the mutant plasmids are available on request. The introduction of the correct mutations for each mutant was confirmed by DNA sequencing.
Recombinant P protein purification and anti-P antibody generation. pET-28a-P, carrying the P gene fused in frame with an N-terminal hexahistidine tag, was transformed into Escherichia coli strain BL21, grown at 37°C to an optical density at 600 nm of 0.5, induced with 1 mM isopropyl-ß-D-thiogalactopyranoside (IPTG), and cultured for another 2 to 4 h at 37°C. After harvest, the cells were resuspended in buffer C (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5 mM MgCl2, 5% glycerol, 0.5% NP-40, 2 mM imidazole, and 7 mM β-mercaptoethanol), lysed by sonication, and centrifuged for 20 min at 8,500 x g and 4°C. Supernatants then were incubated at 4°C for 2 h with equilibrated Ni+-NTA agarose beads (Qiagen). The beads were washed with buffer C containing 20 mM imidazole, and recombinant proteins were eluted in buffer D (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 20% glycerol, 0.1% NP-40, 7 mM β-mercaptoethanol, and 250 mM imidazole). Protein concentrations were determined using a Bio-Rad protein assay. Purified recombinant protein was analyzed on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel by staining with Coomassie brilliant blue.
The recombinant P protein was used as an immunogen. Rabbits (4 weeks old) were immunized with the recombinant P protein with complete Freund's adjuvant. The polyclonal anti-BDV-P antibody was prepared from immunized rabbits' hyperimmune sera by ammonium sulfate precipitation.
T7Select biopanning. A premade T7Select lung cDNA library (no. 70646-3; Novagen) was screened with the T7Select biopanning kit (Novagen) according to the manufacturer's instructions. The P protein expressed from bacteria and purified by affinity chromatography was used as the bait. After five rounds of selection, 96 randomly selected clones were picked up from each library, and the sequences of each of the clones were determined by DNA sequence analysis and searched for homology to known sequences with the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST).
Mammalian two-hybrid analysis. 293T cells or HeLa cells were transfected with luciferase reporter plasmid pG5luc (Promega) and test plasmids, respectively, using Lipofectamine 2000 transfection reagent in 24-well culture plates. Forty-eight hours after transfection, cells were lysed in 100 µl of lysis buffer for 60 min with shaking at room temperature. After centrifugation at 12,000 x g for 5 min at 4°C, the cell extracts were assayed for luciferase activity using the dual-luciferase reporter assay system (Promega) according to the manufacturer's recommendations.
Immunoprecipitation assay. 293T cells were cotransfected with plasmids pCMV-GABARAP expressing Flag-tagged GABARAP and pCDNA-P expressing P protein. Forty-eight hours posttransfection, transfected cells were lysed by freeze-thaw cycling in a buffer containing 10 mM Tris, pH 7.6, 150 mM NaCl, 0.5% NP-40, and 1.0 mM phenylmethylsulfonyl fluoride. After centrifugation, the soluble fraction was immunoprecipitated with anti-P antibody for 2 h at 4°C, and the precipitates then were recovered by incubation with protein A/G-agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 2 h at 4°C. After being thoroughly washed, proteins bound to the agarose beads were separated by SDS-PAGE and electrotransferred onto a polyvinylidene difluoride membrane, which then was blocked with 5% skimmed milk in phosphate-buffered saline (PBS)-0.05% Tween 20 (PBS-T) overnight at 4°C. The membrane was reacted with anti-Flag mouse monoclonal antibody in PBS-T containing 5% skimmed milk for 1 h at room temperature. After being washed, the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) for 1 h at room temperature and visualized by the enhanced chemiluminescence system (Pierce).
To verify the interaction between BDV P protein and endogenous GABARAP, 293T cells were infected with BDV. Protein extracts prepared from infected or noninfected cells were immunoprecipitated with anti-GABARAP antibody (sc-28938; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and detected by anti-P antibody.
Protein pull-down assays. Purified hexahistidine-tagged recombinant proteins (40 µg) were incubated with 300 µl Ni+-NTA agarose beads in 1 ml binding buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5% NP-40, and 1 mM dithiothreitol [DTT]) for 2 h at 4°C. After two washes with 1 ml binding buffer, some of the hybridized beads were analyzed by SDS-PAGE, and the rest of the beads were incubated with extracts of BDV-infected (OL/BDV) or uninfected (OL) cells in 1 ml of hybridization buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.5 mM EDTA, 0.1% NP-40, 1 mM DTT, and 10 mM imidazole) for 1 h at 4°C. Beads then were washed four times with hybridization buffer, and bound proteins were eluted in Laemmli buffer and determined by Western blot analysis.
Laser-scanning confocal microscopy analysis. Recombinant plasmids pAsRed2C1-GABARAP and/or pEGFP-P, pAsRed2C1-GABARAP, pEGFP-P134, and 1.2 µl Lipofectamine 2000 were mixed in 30 µl DMEM for 20 min and then cotransfected into COS-7 cells. Transfected cells were cultured on coverslips in a 24-well plate. Twenty-four to 36 h posttransfection, cells were fixed with 4% paraformaldehyde for 15 min, washed three times with 1x PBS, counterstained with Hoechst 33258 for 10 min, and then washed three times with 1x PBS. Fluorescence was detected by using a confocal laser-scanning microscope (LSM 510 META; Carl Zeiss). For the indirect immunofluorescence assay, BDV-infected COS-7 cells were transfected with plasmid pAsRed2C1-GABARAP and fixed with 4% paraformaldehyde prior to treatment with 0.4% Triton X-100. After a reaction with the optimal anti-P antibody (1:1,000) as the first antibody, cells were stained with secondary anti-rabbit IgG antibodies labeled with fluorescein isothiocyanate. AsRed2 fusion proteins were visualized with red fluorescence. Fluorescence was detected by using a confocal laser-scanning microscope (LSM 510 META). The overlays were processed with Photoshop 7.
Flow cytometry analysis.
293T cells and BDV-infected 293T cells were grown in 6-well plates until 50% confluence and then were transfected with pCMV-
1, pCMV-β2, and PRK5-
2L-GFPN using Lipofectamine reagent (Invitrogen) to express the GABAA-R. The ratio of the mixture of
1-β2-
2-P-GABARAP was 1:1:2:2:2.
1-β2-
2,
1-β2-
2-GABARAP, and
1-β2-
2-P were used as controls in the same ratio and were normalized with empty vector. For BDV-infected 293T cells, the ratio of the mixture of
1-β2-
2-GABARAP was 1:1:2:2.
1-β2-
2 was used as the control in the same ratio.
1-β2-
2 and
1-β2-
2-GABARAP were used in 293T cells as additional controls in the same ratio and were normalized with empty vector.
Forty-eight hours posttransfection, cells were dislodged from the plates with PBS and 50 mM EDTA, placed on ice, spun down at 4°C, resuspended in antibody incubation buffer (PBS, 0.2% bovine serum albumin, and 0.01% sodium azide) containing rabbit anti-green fluorescent protein (GFP) antibody (1:500; Santa Cruz Biotechnology), and incubated on ice for 30 min. Treated cells then were washed three times with cold PBS, resuspended in antibody incubation buffer containing R-PE-labeled goat anti-rabbit secondary antibody (1:100; PTGLAB), and incubated for 30 min, followed by three washes with PBS. Cells then were fixed in PBS and 4% paraformaldehyde for 5 min, washed three times with ice-cold PBS, and held at 4°C until analysis by flow cytometry. Flow cytometry analysis was performed using a flow cytometer (Cytomics Fc500; Beckman Coulter). Fluorochromes excited from the argon laser were observed at 510 nm for GFP and 570 nm for R-PE. A total of 10,000 cells were randomly selected for analysis.
|
|
|---|
![]() View larger version (62K): [in a new window] |
FIG. 1. P protein expression, purification, and antibody preparation. (A) SDS-PAGE of the induction and expression of His-P protein in E. coli BL21. The gels were stained with Coomassie brilliant blue R-250. Lane 1, proteins expressed in BL21 cells transformed with pET-P without IPTG induction; lane 2, proteins expressed in BL21 cells transformed with pET-P and induced with 1 mM IPTG; lane 3, prestained protein markers 0431. (B) SDS-PAGE of purified His-P protein. Lanes 1 and 2, purified His-P protein; lane 3, prestained protein markers 0431. (C) Western blot of antibody-recognized P protein. Lane 1, proteins prepared from OL BDV-infected (OL/BDV) cells detected by Western blotting using polyclonal antibody to P protein; lane 2, protein preparation of uninfected (OL) cells detected by Western blotting using polyclonal antibody to P protein; lane 3, protein preparation of 293T cells transfected with pcDNA-P detected by Western blotting using polyclonal antibody to P protein; lane 4, protein preparation of 293T cells transfected with pCNDA-3 detected by Western blotting using polyclonal antibody to P protein.
|
![]() View larger version (47K): [in a new window] |
FIG. 2. Identification and sequencing of protein interactions with P protein. (A) The nucleotide sequences of a cDNA fragment isolated from a P protein-reactive phage in a phage display-based protein interaction screen. GAATTC and AAGCTT are sequences of restriction sites. Underlined are the nucleotide sequences with homology to the GABARAP gene. (B) Sequence of 117 amino acids translated from the underlined nucleotide sequences of panel A. (C) Results from a BLAST search of the GenBank databases at the NCBI website, which indicated that the sequences of protein expressed from the phage display that interacted with the P protein were 100% homologous to the cellular protein GABARAP.
|
![]() View larger version (29K): [in a new window] |
FIG. 3. Determination of the interaction between BDV P protein and GABARAP in vivo. (A) Determination of the protein-protein interaction in 293T cells by mammalian two-hybrid analysis. 293T cells were cotransfected with pG5luc (a luciferase reporter plasmid), pVP16-P, and pGAL4-GABARAP or with control plasmids. Binding between proteins was monitored by luciferase activity, which was measured 48 h after transfection using the dual-luciferase reporter assay system. Values are expressed as the means plus standard errors of the means (three values per sample). (B) Determination of the protein-protein interaction in 293T cells by in vivo immunoprecipitations. 293T cells were cotransfected with pcDNA-P (expressing P protein) and pCMV-GABARAP (expressing Flag-tagged GABARAP). The immunoprecipitation was performed with anti-P antibody, and the Western blotting was performed with anti-Flag antibody. Lane 1, P protein alone; lane 2, P protein plus GABARAP; lane 3, extracts of untransfected 293T cells; lane 4, GABARAP alone. (C) Determination of the interaction between BDV P protein and endogenous GABARAP in 293T cells by in vivo immunoprecipitations. 293T cells were infected with BDV, and the interaction between proteins was analyzed by immunoprecipitation. In vivo immunoprecipitation was performed with anti-GABARAP antibody or anti-P antibody, and Western blotting was performed with anti-P antibody. Lane 1, 293T cells infected with BDV; lane 2, uninfected cells. (D) Determination of the interaction between BDV P protein and GABARAP in vitro. His-tagged GABARAP was bound to His-bound Sepharose beads. Some of the beads were detected by SDS-PAGE, and the rest were incubated with the extracts of BDV-infected (OL/BDV) or uninfected (OL) cells. After being washed, bound proteins were eluted with elution buffer, separated by SDS-PAGE, and probed with antibodies to P protein or anti-His antibody. Western blotting was performed with anti-P antibody. Lane 1, extracts of BDV-infected (OL/BDV) cells treated with His-GABARAP-bound agarose beads; lane 2, extracts of BDV-infected (OL/BDV) cells treated with unbound agarose beads; lane 3, extracts of uninfected (OL) cells treated with His-GABARAP-bound agarose beads; lane 4, extracts of uninfected (OL) cells treated with unbound agarose beads.
|
The interaction between GABARAP and P protein in vitro also was determined by using protein pull-down analysis. His-tagged GABARAP was generated and immobilized on Ni+-NTA agarose beads. Cell extracts were prepared from OL cells infected with BDV or left uninfected and used in protein pull-down analysis. Results indicated that His-tagged GABARAP protein could specifically pull down the viral P protein (Fig. 3D), as detected by Western blot analysis probing with polyclonal antibodies to the P protein of BDV. Thus, these results demonstrate that BDV P protein interacts with GABARAP in vitro.
C-terminal 27 amino acids of the P protein are essential for its binding to GABARAP.
To dissect the sequences of P protein required for its binding to GABARAP, several P gene deletions encoding the truncated proteins VP16-P
N1, VP16-P
N2, VP16-P
C1, and VP16-P
C2 were generated. Full-length and truncated P genes were fused in frame with the VP16 transactivating domain to generate plasmids pVP16-P, pVP16-P
N1, pVP16-P
N2, pVP16-P
C1, and pVP16-P
C2, which express corresponding peptides (Fig. 4A). The GABARAP gene was fused in frame with the GAL4 DNA-binding domain to create plasmid pGAL4-GABARAP, which expresses the GAL4-GABARAP fusion protein (Fig. 5A). HeLa cells were cotransfected with pGAL4-GABARAP and pVP16-P, pVP16-P
N1, pVP16-P
N2, pVP16-P
C1, or pVP16-P
C2 and tested for the binding of GABARAP with P protein using a GAL4-VP16-based mammalian two-hybrid system.
![]() View larger version (50K): [in a new window] |
FIG. 4. Functional analysis of P protein in its binding to GABARAP by the mammalian two-hybrid system. (A) Schematic representations of P protein deletions and its fusion proteins. The numbers indicate the amino acid positions of BDV P protein. VP16, transactivating domain of VP16. (B) Functional analysis of P protein in its binding to GABARAP by the mammalian two-hybrid system. HeLa cells were cotransfected with the luciferase reporter plasmid pG5luc along with pGAL4-GABARAP, pVP16, pVP16-P, pVP16-P N1, pVP16-P N2, pVP16-P C1, and pVP16-P C2 as indicated. Forty-eight hours posttransfection, cell extracts were prepared and assayed for luciferase activity. The values are expressed as means plus standard errors of the means.
|
![]() View larger version (48K): [in a new window] |
FIG. 5. Functional analysis of GABARAP in its binding to P protein by the mammalian two-hybrid system. (A) Schematic representation of GABARAP deletions and GAL4-GABARAP fusion proteins. The numbers indicate amino acid positions in GABARAP. GAL4, the DNA-binding domain of GAL4. (B) Functional analysis of GABARAP in the binding of P protein by the mammalian two-hybrid system. HeLa cells were cotransfected with luciferase reporter plasmid pG5luc along with pVP16-P, pGAL4-G, pGAL4-G N1, pGAL4-G N2, pGAL4-G C1, and pGAL4-G C2 as indicated. Forty-eight hours posttransfection, cell extracts were prepared and assayed for luciferase activity. The values are expressed as means plus standard errors of the means.
|
N1, or pVP16-P
N2, but they were very low in cells cotransfected with pGAL4-G and pVP6, pVP16-P
C1, or pVP16-P
C2 (Fig. 4B). These results indicated that GAL4-GABARAP could interact with VP16-P, VP16-P
N1, and VP16-P
N2 but failed to bind to VP16-P
C1 and VP16-P
C2. Since both VP16-P
C1 and VP16-P
C2 lacked amino acids 174 to 201 of the P protein, the C-terminal 27 amino acids are essential for the binding of P protein to GABARAP. On the other hand, since VP16-P
N2 contains the C-terminal sequences from amino acids 87 to 201 of the P protein, the C-terminal 114 amino acids are sufficient for the binding of P protein to GABARAP.
Intact GABARAP protein is required for its binding to the viral P protein.
We used a similar strategy to investigate the sequences of GABARAP that are required for their binding to P protein by constructing several deletions of the GABARAP gene encoding the truncated GABARAP proteins GAL4-G, GAL4-G
N1, GAL4-G
N2, GAL4-G
C1, and GAL4-G
C2 (Fig. 5A). Full-length and truncated GABARAP proteins were fused in frame with the GAL4 DNA-binding domain to generate plasmids pGAL4-G, pGAL4-G
N1, pGAL4-G
N2, pGAL4-G
C1, and pGAL4-G
C2. The P protein was fused in frame with the VP16 transactivating domain to yield pVP16-P (Fig. 4A). HeLa cells were cotransfected with pVP16-P and pGAL4-G, pGAL4-G
N1, pGAL4-G
N2, pGAL4-G
C1, and pGAL4-G
C2, respectively, and analyzed for the binding of the P protein with the GABARAP proteins using a GAL4-VP16-based mammalian two-hybrid system. Results indicated that the viral P protein could interact only with the wild-type protein GAL4-G and failed to bind to the four GABARAP mutants GAL4-G
N1, GAL4-G
N2, GAL4-G
C1, and GAL4-G
C2 (Fig. 5B). These results suggested that GABARAP with an intact structure is essential for its binding to BDV P protein.
BDV P protein stimulates the translocation of GABARAP from the cytosol to nuclei. Subcellular localizations of P protein and GABARAP were investigated by examining COS-7 cells transfected with plasmids expressing enhanced GFP-P (EGFP-P) or AsRed2-GABARAP fusion proteins, respectively. The cellular localization of the fusion proteins was visualized by laser-scanning confocal microscopy. Results showed that EGFP-P was localized mainly in nuclei (Fig. 6A) and that AsRed2-GABARAP was uniformly distributed in the cytosol (Fig. 6B). To show the locations of the nuclei, cells were stained with Hoechst.
![]() View larger version (20K): [in a new window] |
FIG. 6. Determination of the subcellular distribution and colocalization of GABARAP and BDV P protein. (A and B) pEGFP-P or pAsRed2C1-GABARAP was transfected individually into COS-7 cells. The expression and distribution of fusion proteins GFP-P (A) and AsRed2-GABARAP (B) in transfected cells were examined by laser-scanning confocal microscopy. (C and D) pAsRed2C1-GABARAP and pEGFP-P or pEGFP-P C1 were cotransfected into COS-7 cells. The colocalization of fusion proteins GFP-P with AsRed2-GABARAP (C) and GFP-P C1 with AsRed2-GABARAP (D) in transfected cells was examined by laser-scanning confocal microscopy with appropriate filters. (E) For investigating the colocalization of P and GABARAP in BDV-infected COS-7 cells, cells were infected with BDV and then transfected with pAsRed2C1-GABARAP. Anti-P antibody was used as the first antibody, and anti-rabbit IgG antibody labeled with fluorescein isothiocyanate (FITC) was used as the second antibody. Proteins were examined by laser-scanning confocal microscopy. To show the location of the nuclei, cells were stained with Hoechst 33258. Scale bar, 20 µm.
|
To evaluate the effects of P protein on the localization of GABARAP, one of the P protein mutants, P
C1 (or P134), was included in the study. In the presence of P
C1, the majority of GABARAP remained in the cytosol of the cells (Fig. 6D). This result was consistent with previous finding that the P
C1 protein failed to interact with GABARAP (Fig. 4). This result also suggested that the translocation of GABARAP from the cytosol to the nuclei in the presence of P protein was due to its interaction with a functional P protein.
To further investigate the effects of P protein on the cellular distribution of GABARAP in infected cells, COS-7 cells were infected with BDV and then transfected with plasmid expressing AsRed2-GABARAP fusion protein. The subcellular distribution of the fusion protein was examined by laser-scanning confocal microscopy. Results showed that the viral P protein also could interact with the fusion protein by shifting the subcellular distributions of AsRed2-GABARAP from the cytosol to the nuclei in BDV-infected COS-7 cells (Fig. 6E).
BDV P protein inhibits the translocation of GABAA-Rs to the cell surface.
The fact that GABARAP interacts with GABAA-Rs and enhances the translocation receptors to the cell membrane prompted us to determine the effect of the P protein on the translocation of GABAA-Rs to the cell surface regulated by GABARAP. 293T cells were cotransfected with plasmids expressing the three subunits of GABAA-Rs (
, β, and GFP-
), GABARAP, and P protein. The numbers of cells with expressed GFP-
and cells with expressed GFP-
on the membrane were measured by flow cytometry analyses. Results showed that the percentage of cells with GABAA-Rs translocated to the cell surface was 35.2% (in the presence of vector), 32.0% (in the presence of P protein), 66.9% (in the presence of GABARAP), and 43.2% (in the presence of GABARAP and P protein) (Fig. 7A and B). These results demonstrated that GABARAP stimulates the translocation of GABAA-Rs to the cell surface as expected, while the BDV P protein inhibits the translocation of GABAA-Rs to the cell surface by blocking the function of GABARAP.
![]() View larger version (38K): [in a new window] |
FIG. 7. Determination of the effect of P protein on GABARAP in the trafficking of GABAA-Rs. (A) 293T cells were cotransfected with plasmids pCMV- 1 (expressing receptor subunit 1), pCMV-β2 (expressing receptor subunit β2), pRK5- 2L-GFPN (expressing receptor subunit 2 and GFP fusion protein 2-GFP), pCMV-GABARAP, and pCMV-P. Forty-eight hours posttransfection, cells were harvested and the receptors translocated on the cell surface were measured as described in Materials and Methods. Data are expressed as percentages of GFP-positive and R-PE-positive cells and as percentages of GFP-positive and R-PE-negative cells. (B) Flow cytometry data were analyzed, and the percentages of GFP, R-PE double-positive cells in GFP single-positive cells were illustrated. A total of 10,000 cells were randomly selected for analysis. (C) BDV-infected 293T cells or uninfected 293T cells were cotransfected with pCMV- 1, pCMV-β2, pRK5- 2L-GFPN, and pCMV-GABARAP. Forty-eight hours posttreatment, cells were harvested and the receptors translocated on the cell surface were measured according to the method described in Materials and Methods. Data are expressed as percentages of GFP-positive and R-PE-positive cells. (D) Flow cytometry data were analyzed, and the percentages of R-PE-positive cells and GFP-positive cells were illustrated. A total of 10,000 cells were randomly selected for analysis.
|
, β, and GFP-
) and GABARAP. Cells with expressed GFP-
and cells with expressed GFP-
on the membrane were measured by flow cytometry analyses. Results showed that the percentage of cells with GABAA-Rs translocated to the cell surface was 43.1% (in the presence of vector), 38.1% (infected with BDV), 70.7% (in the presence of GABARAP), and 41.8% (in the presence of BDV and GABARAP), respectively (Fig. 7C and D). These results further demonstrated that GABARAP stimulates the translocation of GABAA-Rs to the cell surface as expected, while BDV inhibits the translocation of GABAA-Rs to the cell surface through the viral P protein blocking the function of GABARAP. |
|
|---|
To explore the neurological functions of P protein, we used purified P protein as the bait to identify its cellular targets by screening a human cDNA library using a phage display approach. Using this technique, we identified several cellular factors, including HMGB-1 (data not shown) and GABARAP. Previous results from far-Western blotting assays showed that P protein interacts directly with HMGB-1 and inhibits its functions in cultured neural cells (14, 38). GABARAP, a 14-kDa polypeptide, originally was identified as an intracellular protein with sequence similarity to light chain 3 of microtubule-associated proteins 1A and 1B (18). GABARAP can interact with the
2 subunits of GABAA-Rs (35) and facilitate the surface presentation of GABAA-Rs (2, 4).
The direct binding of P protein to GABARAP was confirmed by several independent approaches, such as mammalian two-hybrid assay, coimmunoprecipitation, and protein pull-down analyses. All results were consistent and demonstrated that P protein interacts directly with GABARAP both in vivo and in vitro, indicating that P protein is involved in the regulation of the function of GABAA-Rs.
The C terminus of P protein has been reported to have several functions. Residues 135 to 182 are responsible for its interacting with the viral polymerase (28), and residues 194 to 201 are responsible for its interacting with BDV N protein (30). All the findings demonstrated that the C terminus of P protein is critical for protein-protein interaction. Our data in this study were consistent with these results, which indicated that amino acids 175 to 201 of the P protein are important, and the deletion of this region results in the loss of P protein function in its interaction with GABARAP.
In the process of dissecting functional domains that are responsible for the binding of GABARAP to P protein, we found that the interaction of the viral protein requires an intact full-length GABARAP. It was reported that GABARAP contains two domains, a larger C-terminal domain (residues 27 to 117) that mediates GABAA-R binding (4, 35) and a smaller N-terminal one (residues 1 to 26) that contains a novel tubulin-binding motif (7, 32, 35). Glycine 116 is required for the C-terminal processing of GABARAP, the localization of the protein, and its functions as a trafficking protein (5).
The cellular colocalization of GABARAP and P protein and the status of their interaction were explored in mammalian cells in this study. When the two proteins were expressed separately, BDV P protein was rich in the nucleus, while GABARAP was distributed predominantly in the cytosol, which was consistent with previous reports (29, 31, 37). However, when both proteins were present in the same cells, P protein could bind to GABARAP and recruit GABARAP to P protein-rich loci (in the nucleus). In contrast, the coexpression of the GABARAP protein and the truncated P protein (P
N1) resulted in the failure of P
N1 to bind to GABARAP and in an inhibitory effect on the recruitment of GABARAP from the cytosol to the nucleus. In addition, in BDV-infected COS-7 cells, GABARAP also was distributed in the nuclei of the cells, which is predominantly where the viral P protein was found. These results demonstrated that the viral P protein may play a role in the regulation of the neurological functions of GABARAP.
Previous studies have demonstrated that GABARAP is important for interactions with several cellular transcription factors, including the
2 subunit, tubulin, gephyrin, NSF, ULK1, p130, and transferin GABAA-Rs, resulting in shipping GABAA-Rs to the cell surface, organizing them into postsynaptic clusters, and regulating the steady-state receptor density (4, 6). Our findings raise the possibility that the viral P protein and its cellular partners competitively interfere with each other in binding to GABARAP. Among these cellular factors, GABAA-R subunit
2 is a particularly interesting one, due to the facts that it plays a direct role in neurological functions and that BDV infects a lot of big neurons, including GABA-ergic neurons (11).
Interestingly, in this study we demonstrated that the P protein of BDV inhibits the function of GABARAP in promoting the translocation of GABAA-Rs to the cell surface by using heterologous expression systems. Thus, we predict that BDV P protein inhibits GABA-induced currents based on the previous literature (4, 10), although further studies have to be done in order to confirm this hypothesis. Nevertheless, our results suggested that the BDV P protein plays an important role in the regulation of the neurological functions of the cells, since it has been reported that decreased GABAA-R translocation results in enhanced anxiety and a bias for threat cues (8).
Although the clinical course and histopathology of Borna disease vary with the age of the animal at the time of infection, our results may explain the neurological effects (hyperactivity and enhanced anxiety) in some cases. For example, many experimental data on BDV infection have been obtained in rat models in which the infection of adult immunocompetent rats with BDV causes acute disease characterized by hyperactivity and aggressiveness, followed by tremors, paralysis, and often death (21). Neonatal BDV brain infection results in selective developmental damage to the hippocampal dentate gyrus and the cerebellum. When mature, neonatally BDV-infected rats show extreme locomotor hyperactivity (23). The possible interpretation of these behavioral abnormalities suggests decreased GABAA-R translocation in infected rats compared to that in normal animals.
In summary, we demonstrated that BDV P protein interacts directly with the cellular protein GABARAP, shifts the distribution of GABARAP from the cytoplasm to the nucleus, and inhibits the GABARAP trafficking of GABAA-Rs to the cell membrane (Fig. 8), which may lead to the inhibition of GABA-induced currents and the pathogenesis of neural abnormality caused by BDV infection.
![]() View larger version (77K): [in a new window] |
FIG. 8. Model for the effect of BDV P protein on GABARAP in the trafficking of GABAA-Rs. (A) In the absence of BDV P protein, GABAA-R is the principal GABA-gated ion channel and plays important roles in neural transmission (17). GABARAP distributes in the cytosol of the cells, interacts with the 2 subunit of GABAA-Rs, links GABAA-Rs to microtubules, facilitates the trafficking of GABAA-Rs to the plasma membrane (4, 5), and thus enhances GABA-induced currents (10). ER, endoplasmic reticulum. (B) In the presence of BDV P protein (P) or in BDV-infected cells, P protein binds to GABARAP, shifts the distribution of GABARAP from the cytoplasm to the nucleus, and blocks the trafficking of GABAA-Rs to the cell surface by inhibiting GABARAP translocation, which may result in neural disorder.
|
1, pCMV-β2, and pRK5-
2L-GFPN; Thorsten Wolff and Peter Staeheli for kindly providing plasmid pcDNA-P; and K. Ikuta for the gift of BDV strain H1766. This work was supported by research grants from the Major State Basic Research Development Program of China (973 project nos. 2005CB522901 and 2005CB522905), the National Natural Science Foundation of China (nos. 30570070 and 30730001), the Program for Changjiang Scholars and Innovative Research Team in Universities (no. IRT0745), and the Department of Science Technology of Hubei Province (no. 2005ABC003) to J. Wu.
Published ahead of print on 24 September 2008. ![]()
|
|
|---|
B results in impaired Borna disease virus replication. J. Virol. 79:6043-6051.
B activator (TANK)-binding kinase-1. Proc. Natl. Acad. Sci. USA 102:13640-13645.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»